Synvia’s Post

Grifols, ROVI Pharmaceutical Company o COFARES serán los garantes del suministro de los fármacos esenciales. La UE selecciona a un total de 17 empresas #farmacéuticas españolas para asegurar el suministro. Otras de las firmas seleccionadas han sido Cinfa, Insud Pharma o Galenicum. Completan la lista nacional Bioibericaérica, Ethypharm, GP Pharm, Hplus, #ERN, Laphysan, Medichem Chemicals, Nornna, Ribera Healthcare y Waterbear. En total, Europa ha seleccionado a 97 empresas para asegurar el suministro, entre las que se encuentran también firmas americanas como Pfizer o Johnson & Johnson. https://lnkd.in/dRCvNegT

Prices go up in 3 days, lock in your savings now! Register for Biosimilars LatAm - Colombia 2024 and save! Act now to secure your spot before prices increase at midnight on March 24! Don't miss the exclusive chance to connect with leading experts, discover innovative solutions, expand your expertise, and collaborate. Register now to save up to €173 on the Pharmaceutical Producer / Healthcare Professional pass and €206 on the Equipment, Product or Service Provider pass. The clock is ticking, let's go! https://lnkd.in/dbqYvDUU If you are affiliated with any of the following organizations, reach out for a discount code: 🤝 Alianza de CROs de Mexico (ACROM), Asociación Colombiana de Farmacovigilancia, AMELAF, ASCIF COLOMBIA, BIOINTROPIC, CAPGEN - Cámara Argentina de Productores de Medicamentos Hospitalarios, Cámara de Comercio de Bogotá, Colombia Productiva, FECOER, INNOS - Instituto de Prospectiva e Innovación en Salud, PróGenéricos, ALANAC - Associação dos Laboratórios Farmacêuticos Nacionais, Amepres México, União Farmacêutica de São Paulo UNIFAR , ASINFAR, CANIFARMA, SINDIFARGO #BiosimilarsLatAm #Colombia #Biosimilars

#DiaMundialDelFarmaceutico 2024: “Farmacéuticos: respondiendo a las necesidades sanitarias globales; facilitando soluciones locales”. Felicitación de Olatz Vergniory, patrono de la Fundación Pharmaceutical Care España. #DMF2024 #atencionfarmaceutica #pharmaceuticalcare #ProfesionFarmaceutica #farmacia #farmaceuticos #FarmaciaAsistencial

ROVI Pharma Industrial Services Annual Results 2023 | ROVI Pharmaceutical Company has registered a 1% increase in operating revenue for 2023—the first post-pandemic year—reaching €829.5 million. 📈 The company also experienced a 1% increase in both its third-party manufacturing business revenue, up to €409.3 million; and in pharmaceutical specialties, up to €420.2 million. ✅ In January 2024, the FDA satisfactorily inspected its facility located in Granada, aimed at the manufacturing of the active ingredient for Moderna's mRNA COVID-19 vaccine. This result authorizes Moderna to market in the United States the vaccine manufactured by ROVI Pharmaceutical Company. Months earlier, in September 2023, the FDA had already approved ROVI Pharmaceutical Company's injectable manufacturing plants in Madrid, San Sebastián de los Reyes, and Alcalá de Henares for the filling and finishing of syringes for the same vaccine. 🌐 Additionally, in July 2023, the company achieved for the second consecutive year a world-leading position in the Sustainalytics ESG risk ranking, establishing itself as the first among the 431 evaluated companies in the pharmaceutical industry category.

The U.S. FDA has recently approved Imuldosa, the biosimilar to Stelara (ustekinumab), making it the fifth approved ustekinumab biosimilar in the U.S. Ustekinumab is a monoclonal antibody used to treat autoimmune conditions such as Crohn’s disease and psoriasis. According to launch dates Q1 and Q2 of year 2025 will se an interesting development of the market in the US. Please see my previous article about the market development of Ustekinumab in Europe as well https://lnkd.in/dHtYx5Ad ---- I am Matteo Boemi and I support you in market knowledge and strategy. How? Since 2001, I have been involved in business, market, and competitive intelligence, helping companies define strategies in line with market and competitive scenarios. #corporateintelligence #marketintelligence #competitiveintelligence #pharmaceutical #strategy #marketsmind

The Janssen Pharmaceutical Companies of Johnson & Johnson ha anunciado la presentación de una solicitud de autorización de comercialización (MAA, por sus siglas en inglés) ante la Agencia Europea de Medicamentos (EMA) para la aprobación de la terapia combinada de macitentán 10 mg y tadalafilo 40 mg en un único comprimido para el tratamiento a largo plazo de la Hipertensión Arterial Pulmonar en pacientes adultos con clase funcional (CF) II o III de la OMS. La solicitud se basa en datos del estudio fase 3 A DUE, que demuestran que un comprimido único mejoró significativamente la hemodinámica pulmonar (flujo sanguíneo a través de los vasos pulmonares) en comparación con las monoterapias de macitentán y tadalafilo en pacientes con HAP. #hipertensiónpulmonararterial #JuntosLlegamosAMás #lahpimporta https://lnkd.in/dWi5GfCY

The 16th edition of Healthcare Super Brands has proudly shortlisted six leading names, identified through extensive research analysis conducted by Network 7 Research, and endorsed by esteemed doctors. These companies are now in the running for the prestigious title of "India’s Most Respected Pharmaceutical Company by Medical Professionals.". Globally, pharmaceutical companies and doctors are indispensable components of the healthcare ecosystem. Their collaboration and expertise drive medical advancements, improve patient care, and ensure the effective delivery of healthcare services. Together, they form the backbone of a system dedicated to enhancing health outcomes and fostering medical innovation. India’s Most Respected Pharmaceutical Company by Medical Professionals 2024 Nominees 1.     Glenmark Pharmaceuticals 2.     DIVIS LABORATORIES Divi's Laboratories Limited Nilima Prasad Divi Harshita Garapati 3.     Zuventus Healthcare Limited, Mumbai Shriram Balasubramanian Sudeep Raj 4.     Ipca Laboratories Limited Pranay Godha Ganesh Kumar 5.     Cadila Pharmaceuticals Limited Andreas Kaparidis Vijayesh Gupta 6.     Intas Pharmaceuticals Binish Chudgar Ajay Bhatt #HealthcareSuperBrands #PharmaLeaders2024 #PharmaLeaders To Vote : https://lnkd.in/gNKdXZhK To Know More : https://lnkd.in/g6Rkqx6j

💊Los farmacéuticos, como profesionales de la salud accesibles, desempeñan un papel fundamental a la hora de facilitar el autocuidado de las personas. 🥼Nuestra experiencia y conocimientos permiten a los pacientes tomar las riendas de su salud, ofreciendo una gama de intervenciones que van más allá de la dispensación de medicamentos y abarcan la #educación, la #orientación y el aprovechamiento de las #tecnologíassanitarias para mejorar los resultados en salud. 👉No te pierdas el último informe de International Pharmaceutical Federation (FIP) sobre #autocuidado #farmacia #farmaciacomunitaria #autocuidado #resultadosensalud

Sweden has delivered more important new evidence for improving access to antibiotics. In a recent report The Dental and Pharmaceutical Benefits Agency, TLV found that revenue guarantees are more cost-effective than transferable exclusivity vouchers. “Vouchers lead to high costs of capital for the companies who might want to buy vouchers, decreasing their willingness to pay for them. At the same time, the uncertain pricing of the vouchers mean that investors will demand higher risk-premiums.” Additionally revenue guarantees ensure that the antibiotics are actually available to those who pay for them – vouchers do not guarantee access, even though the country is obliged to pay. Thanks again, Sweden! #amr Carl Björvang Douglas Lundin https://lnkd.in/d6QYU45s

Teva es una de las compañías farmacéuticas líderes en medicamentos genéricos, pero ¿sabes realmente lo que es un medicamento genérico? 💊 Un medicamento genérico es un producto farmacéutico que se comercializa cuando a la marca se le expira la patente, la cual dura unos 10 años. 📅Los medicamentos genéricos contienen los mismos principios activos, forma farmacéutica, dosis y vías de administración que los originales, pero suelen estar disponibles a un menor coste, mejorando el acceso de los pacientes a estos tratamientos. Además, su seguridad y eficacia es la misma que la del medicamento de marca. Según datos de AESEG Medicamentos Genéricos los medicamentos genéricos suponen un ahorro importante, pues reducen el coste de los medicamentos entre un 40 y un 60%. Conoce más datos sobre los medicamentos genéricos en🔎 https://ow.ly/3TZl50RvtHf #TevaSpain